Park Byoung-Jin, Lee Yong-Jae, Lee Hye-Ree, Jung Dong-Hyuk, Na Ha-Young, Kim Hong-Bae, Shim Jae-Yong
Department of Family Medicine, Yonsei University College of Medicine, Seoul, Korea.
Korean J Fam Med. 2012 Jul;33(4):190-6. doi: 10.4082/kjfm.2012.33.4.190. Epub 2012 Jul 25.
This study investigated the effects of Korean red ginseng (KRG) supplementation on metabolic parameters, inflammatory markers, and arterial stiffness in subjects with metabolic syndrome.
We performed a randomized, double-blind, placebo-controlled, single-center study in 60 subjects who were not taking drugs that could affect metabolic and vascular functions. Subjects were randomized into either a KRG (4.5 g/d) group or a placebo group for a 12-week study. We collected anthropometric measurements, blood for laboratory testing, and brachial-ankle pulse wave velocity (baPWV) at the initial (week 0) and final (week 12) visits.
A total of 48 subjects successfully completed the study protocol. Oral administration of KRG did not significantly affect blood pressure, oxidative or inflammatory markers, or baPWV.
We found no evidence that KRG had an effect on blood pressure, lipid profile, oxidized low density lipoprotein, fasting blood glucose, or arterial stiffness in subjects with metabolic syndrome. These findings warrant subsequent longer-term prospective clinical investigations with a larger population.
ClinicalTrials.gov Identifier: NCT00976274.
本研究调查了补充韩国红参（KRG）对代谢综合征患者代谢参数、炎症标志物和动脉僵硬度的影响。
我们对60名未服用可能影响代谢和血管功能药物的受试者进行了一项随机、双盲、安慰剂对照的单中心研究。受试者被随机分为KRG（4.5克/天）组或安慰剂组，进行为期12周的研究。在初始（第0周）和最终（第12周）访视时，我们收集了人体测量数据、用于实验室检测的血液样本以及臂踝脉搏波速度（baPWV）。
共有48名受试者成功完成了研究方案。口服KRG对血压、氧化或炎症标志物或baPWV没有显著影响。
我们没有发现证据表明KRG对代谢综合征患者的血压、血脂谱、氧化型低密度脂蛋白、空腹血糖或动脉僵硬度有影响。这些发现需要随后进行更大规模人群的长期前瞻性临床研究。
ClinicalTrials.gov标识符：NCT00976274。
